Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications

被引：0
|
作者：
Kolberg, H. C. [1 ]
Tomasevic, Z. [2 ]
Demetriou, G. S. [3 ]
Von Minckwitz, G. [4 ]
Fujiwara, Y. [5 ]
Ponomarova, O. [6 ]
Tesch, H. [7 ]
Santi, P. [8 ]
Hanes, V. [9 ]
机构：
[1] Marienhospital gGmbH, Klin Gynakol & Geburtshilfe, Bottrop, Germany
[2] Inst Oncol & Radiol Serbia, Oncol & Radiol, Belgrade, Serbia
[3] Charlotte Mexeke Johannesburg Acad Hosp, Div Med Oncol, Johannesburg, South Africa
[4] German Breast Grp, Neu Isenburg, Germany
[5] Natl Canc Ctr, Tokyo, Japan
[6] RE Kavetsky Inst Expt Pathol, Expt Pathol, Kiev, Ukraine
[7] Hamatol Onkol Gemeinschaftspraxis, Frankfurt, Germany
[8] Ctr Estudos Hematol & Oncol, Hematol & Oncol, Sao Paulo, Brazil
[9] Amgen Inc, Biosimilars Global Dev, Thousand Oaks, CA 91320 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
365 (PB-16
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [31] Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
    Jackisch, C.
    Kim, S. -B.
    Semiglazov, V.
    Melichar, B.
    Pivot, X.
    Hillenbach, C.
    Stroyakovskiy, D.
    Lum, B. L.
    Elliott, R.
    Weber, H. A.
    Ismael, G.
    ANNALS OF ONCOLOGY, 2015, 26 (02) : 320 - 325
  • [32] Trastuzumab deruxtecan vs physician's choice in patients with HER2+unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02
    Krop, Ian
    Park, Yeon H.
    Kim, Sung-Bae
    Borges, Giuliano
    Aksoy, Sercan
    Gregori, Joaquin Gavila
    Roylance, Rebecca
    Lim, Elgene
    Yerushalmi, Rinat
    Zagouri, Flora
    Duhoux, Francois P.
    Fehm, Tanja
    Takano, Toshimi
    Egorov, Anton
    Wu, Iris
    Cathcart, Jillian
    Chu, Changan
    Andre, Fabrice
    CANCER RESEARCH, 2023, 83 (05)
  • [33] Long-term efficacy of trastuzumab biosimilar CT-P6 in patients with HER2-positive early breast cancer: 6-year survival analysis of phase III study results
    Stebbing, J.
    Baranau, Y.
    Baryash, V.
    Moiseyenko, V.
    Boliukh, D.
    Antone, N. Z.
    Manikhas, A.
    Chornobai, A.
    Kim, S. H.
    Ahn, K.
    Park, T.
    Baek, E. H.
    Park, S.
    Lee, S. J.
    Chang, I. S.
    Kim, S. H.
    Lee, J. Y.
    Choi, J. I.
    ANNALS OF ONCOLOGY, 2022, 33 : S212 - S213
  • [34] Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer Final Analysis of the HannaH Phase 3 Randomized Clinical Trial
    Jackisch, Christian
    Stroyakovskiy, Daniil
    Pivot, Xavier
    Ahn, Jin Seok
    Melichar, Bohuslav
    Chen, Shin-Cheh
    Meyenberg, Christoph
    Al-Sakaff, Nedal
    Heinzmann, Dominik
    Hegg, Roberto
    JAMA ONCOLOGY, 2019, 5 (05)
  • [35] Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
    Hannelore Denys
    Corina L. Martinez-Mena
    Marc T. Martens
    Randal G. D’Hondt
    Marie-Pascale L. Graas
    Ella Evron
    Georgeta Fried
    Noa E. Ben-Baruch
    Christof Vulsteke
    Mona M. Van Steenberghe
    Breast Cancer Research and Treatment, 2020, 181 : 97 - 105
  • [36] Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
    Denys, Hannelore
    Martinez-Mena, Corina L.
    Martens, Marc T.
    D'Hondt, Randal G.
    Graas, Marie-Pascale L.
    Evron, Ella
    Fried, Georgeta
    Ben-Baruch, Noa E.
    Vulsteke, Christof
    Van Steenberghe, Mona M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 181 (01) : 97 - 105
  • [37] A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients
    Nodehi, Reza Safaei
    Kalantari, Behjat
    Raafat, Jahangir
    Ansarinejad, Nafiseh
    Moazed, Vahid
    Mortazavizadeh, Seyed Mohammad Reza
    Hosseinzadeh, Mehran
    Ghaderi, Bayazid
    Jenabian, Arash
    Qadyani, Mojtaba
    Haghighat, Shirin
    Allahyari, Abolghasem
    Mirzania, Mehrzad
    Seghatoleslami, Mohammad
    Payandeh, Mehrdad
    Alikhasi, Afsaneh
    Kafi, Hamidreza
    Shahi, Farhad
    BMC PHARMACOLOGY & TOXICOLOGY, 2022, 23 (01):
  • [38] A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients
    Reza Safaei Nodehi
    Behjat Kalantari
    Jahangir Raafat
    Nafiseh Ansarinejad
    Vahid Moazed
    Seyed Mohammad Reza Mortazavizadeh
    Mehran Hosseinzadeh
    Bayazid Ghaderi
    Arash Jenabian
    Mojtaba Qadyani
    Shirin Haghighat
    Abolghasem Allahyari
    Mehrzad Mirzania
    Mohammad Seghatoleslami
    Mehrdad Payandeh
    Afsaneh Alikhasi
    Hamidreza Kafi
    Farhad Shahi
    BMC Pharmacology and Toxicology, 23
  • [39] Real world data on treatment patterns before and after reporting of the KATHERINE trial: A phase 3 study of adjuvant Ado-trastuzumab emtansine (TDM1) versus trastuzumab in early stage HER plus breast cancer
    Margolis, Neil
    Kozlovsky, Vlad
    Flood, William
    Reddy, Sandeep
    CANCER RESEARCH, 2020, 80 (04)
  • [40] Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial
    Esteva, F. J.
    Baranau, Y. V.
    Baryash, V.
    Manikhas, A.
    Moiseyenko, V.
    Dzagnidze, G.
    Zhavrid, E.
    Boliukh, D.
    Stroyakovskiy, D.
    Pikiel, J.
    Eniu, A. E.
    Li, R. K.
    Rusyn, A. V.
    Tiangco, B.
    Lee, S. J.
    Lee, S. Young
    Yu, S. Y.
    Stebbing, J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 839 - 847
12345